Interagency Collaboration for Patient-Centered Antibacterial Drug Development.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 40794656.
- Also identified by DOI 10.1093/cid/ciaf298 and PMC identifier 12341908.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This manuscript presents key advances of the Antibacterial Resistance Leadership Group (ARLG) Innovations Task Force, a collaboration focused on improving endpoints for registrational trials of antibacterial drugs, including health-related quality-of-life measures, for common acute infections. This group includes members from the United States Food and Drug Administration, National Institutes of Health, academia, industry, and patient representatives to amplify patient voices and ensure that the endpoints are meaningful to how patients feel, function, and survive.
Medical subject headings
- Anti-Bacterial Agents
- Drug Development
- Bacterial Infections